title: Involvement of tachykinin NK1 receptors in nociceptin-induced hyperalgesia in mice.
abstract: Intrathecal (i.t.) injection of nociceptin at small doses (3.0 and 30.0 fmol) produced a significant hyperalgesic response as assayed by the tail-flick test. This hyperalgesic effect peaked at 15 min following i.t. administration of nociceptin (3.0 fmol) and returned to control level within 30 min. Hyperalgesia elicited by nociceptin was inhibited dose-dependently by i.t. co-administration of tachykinin NK1 receptor antagonists, CP-99,994 and sendide. A significant antagonistic effect of [D-Phe7, D-His9] substance P (6-11), a selective antagonist for substance P, was observed against the nociceptin-induced hyperalgesia. Pretreatment with i.t. substance P antiserum and i.t. capsaicin resulted in a complete block of the reduced threshold produced by nociceptin. The NK2 receptor antagonist, MEN-10,376 and pretreatment with neurokinin A antiserum did not alter the behavioural effect of nociceptin. The N-methyl-D-aspartate (NMDA) receptor antagonists, dizocilpine (MK-801) and D(-)-2-amino-5-phosphonovaleric acid (D-APV), and L-NG-nitro arginine methyl ester (L-NAME), a nitric oxide synthase inhibitor, failed to inhibit nociceptin-induced hyperalgesia. The results obtained suggest that the hyperalgesic effect of nociceptin may be mediated through tachykinin NK1 receptors in the spinal cord.
authors.affiliation: Department of Biochemistry, Daiichi College of Pharmaceutical Sciences, Fukuoka, Japan.
authors.forename: C
authors.initials: C
authors.lastname: Sakurada
authors.forename: S
authors.initials: S
authors.lastname: Sakurada
authors.forename: S
authors.initials: S
authors.lastname: Katsuyama
authors.forename: J
authors.initials: J
authors.lastname: Sasaki
authors.forename: K
authors.initials: K
authors.lastname: Tan-No
authors.forename: T
authors.initials: T
authors.lastname: Sakurada
mesh_terms: D015763:2-Amino-5-phosphonovalerate / Q000494:pharmacology; D000700:Analgesics / Q000494:pharmacology; D000818:Animals; D016291:Dizocilpine Maleate / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D006930:Hyperalgesia / Q000139:chemically induced / Q000503:physiopathology*; D007278:Injections, Spinal; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D064729:Neurokinin-1 Receptor Antagonists; D018847:Opioid Peptides / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D010446:Peptide Fragments / Q000494:pharmacology; D010880:Piperidines / Q000494:pharmacology; D011761:Pyrrolidonecarboxylic Acid / Q000031:analogs & derivatives; D011930:Reaction Time; D018040:Receptors, Neurokinin-1 / Q000187:drug effects / Q000502:physiology*; D013116:Spinal Cord / Q000187:drug effects* / Q000502:physiology / Q000503:physiopathology; D013237:Stereoisomerism; D013373:Substance P / Q000494:pharmacology; D000097629:Nociceptin
chemical_list: D015763:2-Amino-5-phosphonovalerate; D000700:Analgesics; D016291:Dizocilpine Maleate; D064729:Neurokinin-1 Receptor Antagonists; D018847:Opioid Peptides; D010446:Peptide Fragments; D010880:Piperidines; D011761:Pyrrolidonecarboxylic Acid; D018040:Receptors, Neurokinin-1; D013373:Substance P; D000097629:Nociceptin; C080755:3-(2-methoxybenzylamino)-2-phenylpiperidine; C032292:substance P (6-11)